WO2025002221 - MULTI-SPECIFIC ANTIBODIES COMPRISING ANTIGEN-BINDING DOMAINS SPECIFICALLY RECOGNIZING C5AR1 AND GM-CSFR ALPHA
National phase entry is expected:
Publication Number
WO/2025/002221
Publication Date
02.01.2025
International Application No.
PCT/CN2024/101864
International Filing Date
27.06.2024
Title **
[English]
MULTI-SPECIFIC ANTIBODIES COMPRISING ANTIGEN-BINDING DOMAINS SPECIFICALLY RECOGNIZING C5AR1 AND GM-CSFR ALPHA
[French]
ANTICORPS MULTI-SPÉCIFIQUES COMPRENANT DES DOMAINES DE LIAISON À L'ANTIGÈNE RECONNAISSANT DE MANIÈRE SPÉCIFIQUE C5AR1 ET GM-CSFR ALPHA
Applicants **
STAIDSON (BEIJING) BIOPHARMACEUTICALS CO., LTD.
No.36, Jinghai Er Road, Beijing Economic-Technological Development Area
Daxing District, Beijing 100176, CN
Inventors
HE, Chong
No.36, Jinghai Er Road, Beijing Economic-Technological Development Area
Daxing District, Beijing 100176, CN
ZHAI, Wenwu
No.36, Jinghai Er Road, Beijing Economic-Technological Development Area
Daxing District, Beijing 100176, CN
ZHOU, Zhiwen
No.36, Jinghai Er Road, Beijing Economic-Technological Development Area
Daxing District, Beijing 100176, CN
Priority Data
PCT/CN2023/102813
27.06.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 2984 | |
| EPO | Filing, Examination | 16950 | |
| Japan | Filing | 597 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 8260 |
Total: 29366 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provides multi-specific (e.g., bispecific) antibodies that specifically recognize C5aR1 and GM-CSFRα, and pharmaceutical compositions comprising multi-specific (e.g., bispecific) antibodies that specifically recognize C5aR1 and GM-CSFRα. Also provided are methods of making and using these antibodies.[French]
L'invention concerne des anticorps multispécifiques (par exemple, bispécifiques) qui reconnaissent de manière spécifique C5aR1 et GM-CSFRα, et des compositions pharmaceutiques comprenant des anticorps multispécifiques (par exemple, bispécifiques) qui reconnaissent de manière spécifique C5aR1 et GM-CSFRα. L'invention concerne également des procédés de fabrication et d'utilisation de ces anticorps.